Chronic Migraine: Xeomin Injections

We are studying Xeomin injections to see if they can help reduce the number of migraine days for people with chronic migraines. This trial compares Xeomin to a placebo to evaluate its effectiveness and safety.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Clostridium Botulinum Neurotoxin Type A (150kd)
Clostridium botulinum neurotoxin type A is a substance that temporarily blocks nerve signals to relax muscles and reduce unwanted muscle activity.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Medizinische Universitaet Innsbruck
Univ.-Klinik für Neurologie
Innsbruck, Austria
Landeskrankenanstalten-Betriebsgesellschaft Kabeg
Neurologie
Klagenfurt am Wörthersee, Austria
Pratia Brno s.r.o.
Brno, Czechia

Sponsor: Merz Therapeutics GmbH
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.